Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in Its 110 “Showcase” Retail Stores in the United States and Canada

Apeaz® is the Fifth Company Product to Be Sold in Retails Stores
in the U.S. and Canada

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter medicine
and consumer care products
to improve men’s and women’s health and
respiratory diseases, today announced that it has entered into a
purchase agreement with the nationwide retail store chain Showcase, a
Canadian company for its drug Apeaz®, for arthritis pain relief. Apeaz®
will be available in Showcase’s 110 stores across the United States and
Canada and on its
portal starting mid-August, 2018.

“We are very pleased to have entered into this purchase agreement with
Showcase for our Apeaz® product as we continue the expansion of our
products into select retail stores,” said Dr. Bassam Damaj, the
President and Chief Executive Officer of Innovus Pharma. “Apeaz® is the
fifth Innovus Pharma product to hit the shelves of retail stores in the
U.S. or Canada in addition to Zestra®, Zestra Glide®, Uxor®
(EjectDelay®) and Androferti®.”

The Company’s Apeaz® drug continues to be in demand in both the United
States and Canadian markets with 10,218 units shipped in 2018 through
June 30 in the United States and 10,875 units shipped in Canada since
its launch in that country in mid-April 2018.

About Apeaz®

Apeaz® is an FDA OTC monograph compliant drug for arthritis pain relief.
The product was approved by Health Canada in January 2018 as a Natural
Health Product (“NHP”) for sales in that country for the same indication.

According to Markets & Markets (October 2016 Report Code: MD
4660), the market for the arthritis and other related joint pain is
estimated to be at approximately $850 million in 2016 and projected to
grow at a CAGR of 5.0% during 2017 to 2021. For more information on
Apeaz®, please visit our website at

To the Company’s knowledge, Apeaz® is the only Canadian NHP product
published and commercialized to reduce all signs and symptoms of
arthritis in the collagen induced mouse model. In addition, our
proprietary deep penetration formulation was shown to penetrate the
joint tissues where the inflammation and joint damage take place (J
Immunol April 1, 2009, 182 (1 Supplement) 50.20).

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to

For more information, go to;;;;;;;;;;;;;;;

About Showcase

Showcase is the Home of the Hottest Trends, and the world’s largest
retailer of its kind. With 100+ permanent stores in Canada’s best
shopping centers and the United States, Showcase offers the most fun,
interactive, new, and unique products ever – all in a retail environment
where you can “try it before you buy it.” They call it retail-tainment!
Founded in 1994 in Edmonton AB, Showcase now is coast-to-coast in every
major market across Canada.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the Apeaz® product and other products,
estimated market for its products, and statements about achieving its
other development, growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent filing
on Form S-1, annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC’s website or without charge from the


Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865